



## Viamet Appoints Dr. Volker Herrmann as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2015, – [Viamet Pharmaceuticals, Inc.](#) today announced the appointment of Volker Herrmann, M.D., M.B.A., as Chief Commercial Officer. Dr. Herrmann is an accomplished pharmaceutical executive with extensive experience in sales, marketing, commercial strategy and market access. Prior to joining Viamet, Dr. Herrmann served as Head of Global Strategy, Commercial Development & Global Marketing for the Vaccines Business Unit of Pfizer Inc. At Pfizer, he contributed to the successful performance of several of the most significant brands in the pharmaceutical marketplace.

“Volker’s extensive commercial experience will be invaluable to Viamet as we advance our portfolio of breakthrough drug candidates,” commented Robert Schotzinger, M.D., Ph.D., CEO of Viamet. “His commercial expertise will be critical as we prepare for Phase 3 development and the eventual launch of VT-1161, our best-in-class agent for the oral treatment of onychomycosis and recurrent vulvovaginal candidiasis.”

“I am thrilled to join Viamet given its exceptional pipeline of product candidates,” said Dr. Herrmann. “The company’s current portfolio includes several highly differentiated antifungal agents representing significant market opportunities. In addition, Viamet’s metalloenzyme biology and chemistry technology provides the opportunity for additional high-value programs that address significant unmet medical needs in oncology and orphan diseases.”

Dr. Herrmann brings to Viamet over 15 years of experience in marketing, sales, general management, commercial strategy and market access. At Pfizer, in addition to his most recent role, he held positions of increasing complexity and responsibility, including General Manager of the Integrated Health Business, Global Business Lead for the Pain Franchise, Vice President of the Regional Brand Cluster for CNS/Pain for Europe, Canada and Australia, and several senior leadership roles in the German Pfizer affiliate.

Dr. Herrmann received his Doctor of Medicine with Honors from the Albert-Ludwigs Universität Freiburg. He also received a Master of Business Administration degree from the University of San Diego, Graduate School of Business.

### **About Metalloenzymes**

Enzymes are complex proteins that help to accelerate biochemical reactions in the body. Metalloenzymes are unique in that they contain a metal atom, commonly iron or zinc, at the center of the enzyme active site. Since many metalloenzymes have been clearly associated with disease, the metal in the enzyme is commonly a target for pharmaceutical intervention. It is estimated that approximately 10% of marketed drugs act by blocking metalloenzyme activity. Inhibitors of metalloenzymes are found across numerous therapeutic indications and many of the inhibitors have achieved blockbuster commercial status. The development of new metalloenzyme inhibitors remains a core focus of the pharmaceutical industry today and the primary focus for Viamet.

### **About Viamet ([www.viamet.com](http://www.viamet.com))**

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior safety and efficacy profiles compared to currently marketed drugs.

***Media Contact:***

Blair McCarthy Atkinson  
MacDougal Biomedical Communications  
Direct: +1 812 454 6257  
Main: +1 781 235 3060  
[batkinson@macbiocom.com](mailto:batkinson@macbiocom.com)

***Investor Contact:***

John Woolford  
Westwicke Partners  
Direct: +1 443 213 0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.